System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jean-Philippe Metges is an expert in Oncology at Centre Hospitalier Régional Universitaire de Brest (France). As of September 2026, ScienceLeadR ranks Jean-Philippe Metges in the top 1% of experts worldwide for Carcinoma and Gastrointestinal Neoplasms, and in the top 1% of experts in France for Stomach Neoplasms. Jean-Philippe Metges has authored 237 publications, the most recent in 2026, and is an investigator in 52 clinical trials, 24 of them ongoing. SLR score: 1,552 (community average: 125). How the SLR is computed.

LeadR Profile

Jean-Philippe Metges Centre Hospitalier Régional Universitaire de Brest France
1 552 ScienceLeadR Reputation 1552

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Biochemistry - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Centre Hospitalier Régional Universitaire de Brest

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 237

Citations

Citations: 13 291 1st author: 29 Last author: 16 Unique author: 2

Main journals

J Clin Oncol 78
Ann Oncol 33
Oncologie (Paris) 12
Eur J Cancer 8
Bull Cancer 7

Best Journals

J Clin Oncol 42
Ann Oncol 14
N Engl J Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma.
PMID 41930113 — positron emission tomography computed tomography, therapeutics		Front Med (Lausanne)20260
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
PMID 41840238 — safety, esophagogastric junction, neoplasms, adenocarcinoma, nivolumab, therapeutics		Nat Med Top journal20260
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.
PMID 41747585 — esophagogastric junction, neoplasms, adenocarcinoma, drug therapy, fluorouracil, stomach neoplasms, chemotherapy		ESMO Open20260
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.
PMID 41337860 — neoplasms, fluorouracil, everolimus, streptozocin, neuroendocrine tumors, therapeutics		ESMO Open20250
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.
PMID 41264278 — biliary tract neoplasms, neoplasms, biliary tract		JAMA Oncol20250

Clinical Studies 52

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 3 21
Phase 2 18
Phase 1/Phase 2 6
N/A 5
Phase 1 2

By status:

Recruiting 24
Completed 16
Active not recruiting 7
Terminated 2
Unknown 2
Not yet recruiting 1

By type:

Interventional 48
Observational 4

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 7
multicentricup10 42

Main Topics

Ongoing Clinical Trials

24 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical study of different study medicines and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK 3475 06E)
2024-514273-22-00 — cells, carcinoma, squamous cell, neoplasms, drug therapy, esophageal squamous cell carcinoma, esophageal neoplasms, chemotherapy, carcinoma		Phase 1/Phase 2Recruiting2025
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors
2023-507555-29-00 — breast neoplasms, pharmaceutical preparations, esophagogastric junction, neoplasms, adenocarcinoma, breast, therapeutics, stomach neoplasms		Phase 1/Phase 2Active not recruiting2024
ENGIC 06 (PRODIGE 114) FFCD 2401 FRUQUITAS Randomized phase III trial to compare trifluridine tipiracil Fruquintinib versus trifluridine tipiracil alone for metastatic oeso gastric adenocarcinoma
2025-522395-92-00 — trifluridine, adenocarcinoma		Phase 3Recruiting2025
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gastric or gastroesophageal junction cancers with high levels of a protein called CLDN18 2
2023-508276-11-00 — staphylococcal protein a, esophagogastric junction, neoplasms, adenocarcinoma, multiple chronic conditions, therapeutics, claudins, stomach neoplasms		Phase 3Active not recruiting2025
A clinical trial of ifinatamab deruxtecan in people with advanced esophageal cancer (MK 3475 06F)
2026-525213-31-00 — cells, carcinoma, squamous cell, neoplasms, esophageal squamous cell carcinoma, esophageal neoplasms, carcinoma		Phase 2Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS